Viewing Study NCT02383966


Ignite Creation Date: 2025-12-24 @ 4:36 PM
Ignite Modification Date: 2026-01-11 @ 5:06 PM
Study NCT ID: NCT02383966
Status: COMPLETED
Last Update Posted: 2022-05-13
First Post: 2015-03-04
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
Sponsor: Merck KGaA, Darmstadt, Germany
Organization: